相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy
Xiaosa Chang et al.
ACTA PHARMACEUTICA SINICA B (2021)
Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development
Pan Tang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions
Minru Liao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Targeting autophagy-related protein kinases for potential therapeutic purpose
Honggang Xiang et al.
ACTA PHARMACEUTICA SINICA B (2020)
Targeting mTOR for fighting diseases: A revisited review of mTOR inhibitors
Tian Xu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in Triple-negative Breast Cancer
Yongqi Zhen et al.
THERANOSTICS (2020)
A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy
Chia-Hao Chang et al.
AUTOPHAGY (2019)
Breast Cancer Treatment A Review
Adrienne G. Waks et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Further Progress for Patients with Breast Cancer
Daniel F. Hayes
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Small-Molecule Activator of UNC-51-Like Kinase 1 (ULK1) That Induces Cytoprotective Autophagy for Parkinson's Disease Treatment
Liang Ouyang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
mTOR Cross-Talk in Cancer and Potential for Combination Therapy
Fabiana Conciatori et al.
CANCERS (2018)
Mammalian target of rapamycin ( mTOR) as a potential therapeutic target in various diseases
Avileen Kaur et al.
INFLAMMOPHARMACOLOGY (2017)
Inhibition of PI3K/AKT/mTOR signaling pathway promotes autophagy of articular chondrocytes and attenuates inflammatory response in rats with osteoarthritis
Jian-Feng Xue et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma
Qiwen Fan et al.
CANCER CELL (2017)
mTOR Signaling in Growth, Metabolism, and Disease
Robert A. Saxton et al.
CELL (2017)
PI3K/Akt/mTOR activation by suppression of ELK3 mediates chemosensitivity of MDA-MB-231 cells to doxorubicin by inhibiting autophagy
Ji-Hoon Park et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
Clinical and molecular complexity of breast cancer metastases
Siker Kimbung et al.
SEMINARS IN CANCER BIOLOGY (2015)
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease
Murugan Kalimutho et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers
Sylvain Lefort et al.
AUTOPHAGY (2014)
Clioquinol induces pro-death autophagy in leukemia and myeloma cells by disrupting the mTOR signaling pathway
Biyin Cao et al.
SCIENTIFIC REPORTS (2014)
Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia
M. R. Janes et al.
LEUKEMIA (2013)
mTOR kinase structure, mechanism and regulation
Haijuan Yang et al.
NATURE (2013)
Mst1 inhibits autophagy by promoting the interaction between Beclin1 and Bcl-2
Yasuhiro Maejima et al.
NATURE MEDICINE (2013)
Temsirolimus Activates Autophagy and Ameliorates Cardiomyopathy Caused by Lamin A/C Gene Mutation
Jason C. Choi et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Rapamycin passes the torch: a new generation of mTOR inhibitors
Don Benjamin et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling
Peggy P. Hsu et al.
SCIENCE (2011)
Finding a fitting shoe for Cinderella Searching for an autophagy inhibitor
Simon Miller et al.
AUTOPHAGY (2010)
AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
Christine M. Chresta et al.
CANCER RESEARCH (2010)
PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality
Elena Lopez-Knowles et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases
Beth Apsel et al.
NATURE CHEMICAL BIOLOGY (2008)
Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-Deficient glioblastoma
Tim F. Cloughesy et al.
PLOS MEDICINE (2008)
Role of autophagy in breast cancer
Vassiliki Karantza-Wadsworth et al.
AUTOPHAGY (2007)
Total synthesis of rapamycin
Matthew L. Maddess et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2007)
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Qi-Wen Fan et al.
CANCER CELL (2006)
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton
DD Sarbassov et al.
CURRENT BIOLOGY (2004)
mTOR: a protein kinase switching between life and death
L Asnaghi et al.
PHARMACOLOGICAL RESEARCH (2004)
Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease
B Ravikumar et al.
NATURE GENETICS (2004)
Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action
K Hara et al.
CELL (2002)
Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients
G Pérez-Tenorio et al.
BRITISH JOURNAL OF CANCER (2002)
分享论文
